Patient leaflet - Olanzapine Glenmark
1. What Olanzapine Glenmark is and what it is used for
Olanzapine Glenmark contains the active substance olanzapine. Olanzapine Glenmark belongs to a group of medicines called antipsychotics.
Olanzapine Glenmark is used to treat the following conditions:
- Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense.
- Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria.
Olanzapine Glenmark has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
2. What you need to know before you take Olanzapine GlenmarkDo not take Olanzapine Glenmark- if you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine
(listed in section 6). An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor.
-
– if you have been previously diagnosed with eye problems such as certain kinds of glaucoma
(increased pressure in the eye).
Warnings and precautions
Talk to your doctor or pharmacist before you take Olanzapine Glenmark
-
– The use of Olanzapine Glenmark in elderly patients with dementia is not recommended as it may have serious side effects.
-
– Medicines of this type may cause unusual movements mainly of the face or tongue. If this happens after you have been given Olanzapine Glenmark tell your doctor.
-
– Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your doctor at once.
-
– Weight gain has been seen in patients taking Olanzapine Glenmark. You and your doctor should check your weight regularly. Consider referral to a dietician or help with a diet plan if necessary.
-
– High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Glenmark. Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Glenmark and regularly during treatment.
-
– Tell your doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.
If you suffer from any of the following illnesses tell your doctor as soon as possible:
- Stroke or “mini” stroke (temporary symptoms of stroke)
- Parkinson’s disease
- Prostate problems
- A blocked intestine (Paralytic ileus)
- Liver or kidney disease
- Blood disorders
- Heart disease
- Diabetes
- Seizures
- If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)
If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or “mini” stroke.
As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.
Children and adolescents
Olanzapine Glenmark is not for patients who are under 18 years.
Other medicines and Olanzapine Glenmark
Only take other medicines while you are on Olanzapine Glenmark if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Tell your doctor if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor if you are taking:
- Medicines for Parkinson’s disease
- Carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepresant) or ciprofloxacin (an antibiotic) – it may be necessary to change your Olanzapine Glenmark dose.
Olanzapine Glenmark with alcohol
Do not drink any alcohol if you have been given Olanzapine Glenmark as together with alcohol it may make you feel drowsy.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Glenmark can pass into breast milk.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.
Driving and using machines
There is a risk of feeling drowsy when you are given Olanzapine Glenmark. If this happens do not drive or operate any tools or machines. Tell your doctor.
Olanzapine Glenmark contains aspartame
Olanzapine Glenmark contains a source of phenylalanine. This may be harmful for people with phenylketonuria.
3. How to take Olanzapine Glenmark
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will tell you how many Olanzapine Glenmark tablets to take and how long you should continue to take them. The daily dose of Olanzapine Glenmark is between 5 mg and 20 mg. Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark unless your doctor tells you to.
You should take your Olanzapine Glenmark tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food. Olanzapine Glenmark tablets are for oral use. You should swallow the Olanzapine Glenmark tablets whole, with water.
If you take more Olanzapine Glenmark than you should
Patients who have taken more Olanzapine Glenmark than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away if you experience any of the above symptoms. Show the doctor your pack of tablets.
If you forget to take Olanzapine Glenmark
Take your tablets as soon as you remember. Do not take two doses in one day.
If you stop taking Olanzapine Glenmark
Do not stop taking your tablets just because you feel better. It is important that you carry on taking Olanzapine Glenmark for as long as your doctor tells you.
If you suddenly stop taking Olanzapine Glenmark, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to reduce the dose gradually before stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately if you have:
- unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;
- blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately;
- a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).
Very common side effects (may affect more than 1 in 10 people) include:
- Weight gain
- Sleepiness
- Increases in the levels of prolactin in the blood.
- In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.
Common side effects (may affect up to 1 in 10 people) include:
- Changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes.
- Increases in the level of sugars in the blood and urine.
- Increases in levels of uric acid and creatine phosphokinase in the blood
- Feeling more hungry.
- Dizziness.
- Restlessness.
- Tremor.
- Unusual movements(dyskinesias)
- Constipation.
- Dry mouth.
- Rash.
- Loss of strength.
- Extreme tiredness.
- Water retention leading to swelling of the hands, ankles or feet.
- Fever
- Joint pain
- Sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Uncommon side effects (may affect up to 1 in 100 people) include:
- Hypersensitivity (e.g. swelling in the mouth and throat, itching, rash)
- diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma
- seizures, usually associated with a history of seizures (epilepsy)
- muscle stiffness or spasms (including eye movements)
- restless legs syndrome
- problems with speech
- Stuttering
- Slow heart rate.
- Sensitivity to sunlight.
- Bleeding from the nose.
- Abdominal distension
- Drooling
- Memory loss or forgetfulness
- Urinary incontinence, lack of ability to urinate.
- Hair loss.
- Absence or decrease in menstrual periods.
- Changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Rare side effects (may affect up to 1 in 1000 people) include:
- Lowering of normal body temperature.
- Abnormal rhythms of the heart.
- Sudden unexplained death.
- Inflammation of the pancreas causing severe stomach pain, fever and sickness.
- Liver disease appearing as yellowing of the skin and white parts of the eyes.
- Muscle disease presenting as unexplained aches and pains.
- Prolonged and/or painful erection.
Very rare side effects (may affect up to 1 in 10,000) include:
- Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia).
While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients.
In patients with Parkinson’s disease Olanzapine Glenmark may worsen the symptoms.
Reporting side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Olanzapine Glenmark
Keep this medicine out of sight and reach of children
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Store below 30° C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other informationWhat Olanzapine Glenmark contains- The active substance is olanzapine
-
– Each Olanzapine Glenmark tablet contains 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine
-
– The other ingredients are mannitol (E 421), microcrystalline cellulose, aspartame (E 951),
What Olanzapine Glenmark looks like and contents of the pack
Olanzapine Glenmark 2.5mg:
yellow coloured circular flat bevelled edge tablets with ‘A’ debossed on one side.
Olanzapine Glenmark 5 mg:
yellow coloured circular flat bevelled edge tablets with ‘B’ debossed on one side.
Olanzapine Glenmark 7.5 mg:
yellow coloured circular flat bevelled edge tablets with ‘C’ debossed on one side.
Olanzapine Glenmark 10 mg:
yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘D’ debossed on other side.
Olanzapine Glenmark 15 mg:
yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘E’ debossed on other side.
Olanzapine Glenmark 20 mg:
yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘F’ debossed on other side.
Olanzapine Glenmark 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg are available in aluminium foil blisters of 28, 56, 70 and 98tablets
Olanzapine Glenmark 20 mg tablets are available in aluminium foil blisters of 28, 35, 56, 70 and 98 tablets
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Glenmark Arzneimittel GmbH
Industriestr. 31, 82194
Gröbenzell, Germany
Manufacturer
Glenmark Pharmaceuticals s.r.o.
City Tower, Hvezdova 1716/2b, 140 78 Praha 4
Czech Republic
Glenmark Pharmaceuticals Europe Limited
Building 2, Croxley Green Business Park,
Croxley Green
Hertfordshire, WD18 8YA,
United Kingdom
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
België/Belgique/Belgien Luxembourg/Luxemburg
Glenmark Arzneimittel GmbH, Germany Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199 Tel: + 49 (8142) 44392 199
Bt^rapuH
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Magyarorszag
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Česká republika
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Danmark
Glenmark Pharmaceuticals Nordic AB
Tél/Tel: + 46 (0) 40 35 48 10
Deutschland
Glenmark Arzneimittel GmbH
Tel: + 49 (8142) 44392 0
Eesti
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
EZZáóa
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
España
Viso Farmacéutica S.L.U
Tél/Tel: + 34 911 593 944
France
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Hrvatska
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Ireland
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Ísland
Glenmark Pharmaceuticals Nordic AB
Tél/Tel: + 46 (0) 40 35 48 10
Italia
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Kùnpoç
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Latvija
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Lietuva
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Malta
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Nederland
Glenmark Pharmaceuticals B.V.
Tél/Tel: + 31 629 62 4818 / +31 40 245 3611
Norge
Glenmark Pharmaceuticals Nordic AB
Tél/Tel: + 46 (0) 40 35 48 10
Österreich
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Polska
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Portugal
Glenmark Arzneimittel GmbH
Tel: + 49 (8142) 44392 199
România
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Slovenija
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Slovenská republika
Glenmark Arzneimittel GmbH, Germany
Tel: + 49 (8142) 44392 199
Suomi/Finland
Glenmark Pharmaceuticals Nordic AB
Tél/Tel: + 46 (0)40 35 48 10
Sverige
Glenmark Pharmaceuticals Nordic AB
Tél/Tel: + 46 (0)40 35 48 10
United Kingdom
Glenmark Pharmaceuticals Europe Limited
Tél/Tel: + 44 (0) 800 4580 383/0 1923 693939
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency website:
123
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), _______
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body
weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and >
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), _______
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body
weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and >
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), _______
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and > 25 % was common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained > 7 %, 55.3 % gained > 15 % and 29.1 % gained > 25% of their baseline body weight.
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (> 1.467
mmol/l) and changes in fasting triglycerides from borderline at baseline (> 1.016 mmol/l – < 1.467
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), ______
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and > 25 % was common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained > 7 %, 55.3 % gained > 15 % and 29.1 % gained > 25% of their baseline body weight.
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (> 1.467
mmol/l) and changes in fasting triglycerides from borderline at baseline (> 1.016 mmol/l – < 1.467
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), _______
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and > 25 % was common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained > 7 %, 55.3 % gained > 15 % and 29.1 % gained > 25% of their baseline body weight.
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (> 1.467
mmol/l) and changes in fasting triglycerides from borderline at baseline (> 1.016 mmol/l – < 1.467
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4,4), _________
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Following short term treatment (median duration 22 days), weight gain > 7 % of baseline body weight (kg) was very common (40.6 %), > 15 %of baseline body weight was common (7.1 %) and > 25 % was common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained > 7 %, 55.3 % gained > 15 % and 29.1 % gained > 25% of their baseline body weight.
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (> 1.467
mmol/l) and changes in fasting triglycerides from borderline at baseline (> 1.016 mmol/l – < 1.467